Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects

The pharmacokinetics and tolerability of nebulized MP-376 (levofloxacin inhalation solution [Aeroquin]) were determined in cystic fibrosis (CF) subjects. Ten CF subjects received single 180-mg doses of two formulations of MP-376, followed by a multiple-dose phase of 240 mg once daily for 7 days. Ser...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Antimicrobial agents and chemotherapy Jg. 55; H. 6; S. 2636
Hauptverfasser:	Geller, David E, Flume, Patrick A, Griffith, David C, Morgan, Elizabeth, White, Dan, Loutit, Jeffery S, Dudley, Michael N
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.06.2011
Schlagworte:	Administration, Inhalation Adolescent Adult Anti-Bacterial Agents - pharmacokinetics Area Under Curve Cross-Over Studies Cystic Fibrosis - drug therapy Female Humans Levofloxacin Male Middle Aged Ofloxacin - adverse effects Ofloxacin - pharmacokinetics Single-Blind Method Solutions
ISSN:	1098-6596, 1098-6596
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!